Cellosaurus cell line UACC-2534 (CVCL_M452)

PubMed=10952317; DOI=10.1038/35020115
Bittner M., Meltzer P.S., Chen Y.-D., Jiang Y., Seftor E.A., Hendrix M.J.C., Radmacher M.D., Simon R.M., Yakhini Z., Ben-Dor A., Sampas N., Dougherty E., Wang E., Marincola F.M., Gooden C., Lueders J., Glatfelter A., Pollock P.M., Carpten J.D., Gillanders E.M., Leja D., Dietrich K., Beaudry C., Berens M.E., Alberts D.S., Sondak V.K., Hayward N.K., Trent J.M.
Molecular classification of cutaneous malignant melanoma by gene expression profiling.
Nature 406:536-540(2000)

PubMed=23039341; DOI=10.1186/1476-4598-11-75
Byron S.A., Loch D.C., Wellens C.L., Wortmann A., Wu J.-Y., Wang J., Nomoto K., Pollock P.M.
Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.
Mol. Cancer 11:75.1-75.15(2012)

PubMed=24879157; DOI=10.4161/auto.28594
Goodall M.L., Wang T., Martin K.R., Kortus M.G., Kauffman A.L., Trent J.M., Gately S., MacKeigan J.P.
Development of potent autophagy inhibitors that sensitize oncogenic BRAF V600E mutant melanoma tumor cells to vemurafenib.
Autophagy 10:1120-1136(2014)